(Total Views: 549)
Posted On: 05/01/2022 5:30:54 PM
Post# of 153903
Thanks for posting the link, handy timelines to rehash.
As for Goose asking what the patient count is in Brazil trials, Dr. Kelly shared during the recent CC during Q&A that critical was at 16 with 38 sites active & severe was 77 patients with 38 sites active-
And looking back through my notes from shareholder meeting in late November I was struck again by how excited Dr. Recknor was about what he was seeing in the NASH & LH trial results.
Quotes like "Seeing reduction in fibrosis across mild, moderate & advanced patients" -- " Has implications for other organs & "prospects are amplified moving forward". And finally " In LH trial saw dramatic improvement in osteoarthritis - "seeing very similar signals from LH to NASH"
With human data continuing to roll in, they're finding new & unexpected methods of MOA ( and hopefully validating prior known MOA) and that
has to pique the interest of BP & partners worldwide--
As for Goose asking what the patient count is in Brazil trials, Dr. Kelly shared during the recent CC during Q&A that critical was at 16 with 38 sites active & severe was 77 patients with 38 sites active-
And looking back through my notes from shareholder meeting in late November I was struck again by how excited Dr. Recknor was about what he was seeing in the NASH & LH trial results.
Quotes like "Seeing reduction in fibrosis across mild, moderate & advanced patients" -- " Has implications for other organs & "prospects are amplified moving forward". And finally " In LH trial saw dramatic improvement in osteoarthritis - "seeing very similar signals from LH to NASH"
With human data continuing to roll in, they're finding new & unexpected methods of MOA ( and hopefully validating prior known MOA) and that
has to pique the interest of BP & partners worldwide--
(13)
(0)
